jollibee 6 pcs www jilibet.com jollibee breakfast menu ubet casino login jolibet 3 login
Current location: jilibet slots > jollibee 6 pcs > reddit sport betting

reddit sport betting

Release time: 2025-01-14 | Source: Unknown
UNITED KINGDOM - DECEMBER 23: Raindrops on glass (Photo by Tim Graham/Getty Images) It seems ridiculous to think that you could reduce something like amino acid interactions and resulting proteins to the level of something like Minecraft. In fact, I wouldn’t think most of us have even considered how generative AI could be applied to life science. But a few people behind the scenes are working diligently on figuring this out. Geoff von Maltzahn is at Flagship Pioneering, a company that’s working on the vanguard of high-tech life science. This venture capital firm has an incubator and teams of scientists and entrepreneurs working on things like mRNA and antibody therapeutics, as well as broader genomic projects. Flagship Pioneering works with companies like Seres Therapeutics and Indigo Agriculture, to innovate in places where breakthrough scientific progress can help with the biggest challenges that we as humans face. In a compelling TED talk, Maltzahn illustrates how all of this can work. He starts with a basic explanation of protein folding, where individual proteins emerge through a process of evolution that biologists tend to understand fairly well, while the rest of us have don’t have much of a clue. The World of Proteins Part of what I thought was so great about this talk was that Maltzahn really breaks down formidable scientific ideas into words that many people can easily understand. For example, in showing how a protein structure evolves, he notes that each protein starts out as a ‘noodle’ and then folds itself into useful forms. “This is the equivalent of, if your car, your refrigerator, your house, arrived as a noodle and folded itself into the form that you enjoy it in,” he says. Russian Officers Pulled Over For A Hasty Meeting. That’s When A Ukrainian HIMARS Opened Fire. Apple Cancels iPhone 14 And iPhone SE For Millions Of Users iOS 18.2.1 Release Date: New Apple iPhone Update Confirmed After explaining protein folding, he explains that new systems are able to generate models of proteins that fold in very precise ways. Maltzahn talks the prospect of about pursuing a ‘Shakespearean mastery’ of protein writing. His metaphor on precision and archery, again, boils down this type of innovation into a sort of visual reference in explaining how systems can center on the creation of precise antibodies: “It’s kind of like Robin Hood splitting the first arrow by firing an arrow right down the center of it, 50 times in a row,” he says. “And the reason that it has the potential to be valuable is: every time an antibody shows ... that it can provide a benefit to patients, humanity has a benefit, the ability to access the very best antibody.” In aid of talking about the best antibodies, he also goes over specifically how to react against the Covid virus that created the universal pandemic we all suffered through. He explains that to keep viruses from entering the cells, the technology can build antibodies that go after that portion that’s attaching to receptors. “This may be important to the next pandemic,” Maltzahn says. More New Science In addition, Maltzahn talks about creating new enzymes and analyzing things like the ‘tree of life of SARS viruses’ and how that will lead to very profound discoveries. “Maybe generative AI isn't just going to create beautiful cartoons and limericks to entertain ourselves and one another, and access knowledge that is already resident within humanity,” he posits. “It may just expand our access to new knowledge and new technologies in important ways.” How big will this be? The space of unexplored biology he explains is vast. Mentioning an analogy to the ‘great age of exploration’ with ships, he says we have worlds of knowledge to discover. “Even with generous assumptions around everything Mother Nature has ever had the chance to build and test throughout the entire history of evolution, all of her lab has tested less than the expanse of one drop of water relative to all of the Earth's oceans of possible protein sequences,” he says. “Think about that for just a second. Everybody in this room, every protein that makes our lives possible, every one of our ancestors and everything else in the living world that has ever been, fits into that one drop of water. ... if everything we know is in that one drop of water, if we find one more drop of water, that'll be a really big deal. But there really isn't a reason to believe that it's going to be limited to that, just imagine what could be.” I’ve seen and heard a lot about AI in the past year, but this is something fairly unique that really deserves a close look. We’re just beginning to understand how AI can create digital worlds that are vibrant, unique, and compelling, and how it can think like humans. But being able to create in a godlike way, using the building blocks of all life– well, to put it simply, that that’s something else.Smith asks to drop casesDonald Trump is returning to the world stage. So is his trollingreddit sport betting 。

AP Trending SummaryBrief at 4:43 p.m. ESTTHE WOODLANDS, TX, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix” or the "Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced the closing of its previously announced underwritten public offering of common stock units and pre-funded warrant units for aggregate gross proceeds of approximately $10.0 million, prior to deducting underwriting discounts and commissions and offering expenses, which amount includes the partial exercise of the over-allotment option granted to the underwriter. The equity offering was comprised of 615,500 common stock units (which included 156,809 common stock units issued upon exercise of the underwriter's over-allotment option) and 917,596 pre-funded warrant units, priced at a public offering price of $6.54 per common stock unit and $6.539 per pre-funded warrant unit. Each common stock unit and pre-funded warrant unit consisted of one share of common stock (or, in lieu of common stock, a pre-funded warrant to purchase one share of common stock at an exercise price of $0.001) and one warrant to purchase one share of common stock that expires on the five-year anniversary of the date of issuance (a "Series A Warrant"). The exercise price for the Series A Warrant is $6.54 per share. The warrants issued in this transaction were fixed priced and do not contain any variable pricing features. The securities comprising the units were immediately separable and were issued separately. Ladenburg Thalmann & Co. Inc. acted as the sole bookrunning manager for the offering. The Company intends to use the net proceeds from this offering to fund its clinical trial, for other research and development, for development of intellectual property, and for working capital. The securities described above were offered by the Company pursuant to a registration statement on Form S-1 (No. 333-282940), which was declared effective by the Securities and Exchange Commission (the "SEC”) on November 22, 2024. The offering was made solely by means of a prospectus. A final prospectus relating to and describing the terms of the offering was filed with the SEC on November 25, 2024 and is available on the SEC's website at http://www.sec.gov. Electronic copies of the final prospectus may be obtained from Ladenburg Thalmann & Co. Inc., 640 Fifth Avenue, 4th Floor, New York, New York 10019, or by telephone at (212) 409-2000, or by email at [email protected] . This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About Autonomix Medical, Inc. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States. Forward Looking Statements Some of the statements in this release are "forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation the use of the anticipated proceeds from the offering. Such forward-looking statements can be identified by the use of words such as "should,” "might,” "may,” "intends,” "anticipates,” "believes,” "estimates,” "projects,” "forecasts,” "expects,” "plans,” and "proposes.” Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission ("SEC”) on May 31, 2024, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law. Investor and Media Contact JTC Team, LLC Jenene Thomas 908-824-0775 [email protected]



Malik Nabers bemoans lack of early targets after ‘soft’ Giants’ blowout loss to Buccaneers

( MENAFN - ForPressRelease) Luxota, a leader in innovative travel technology, has officially launched White-label Xpert, enabling online travel agencies (OTAs) to offer fully branded, operational platforms to their B2B clients. This new solution is set to redefine how travel agencies collaborate with their partners by providing an independent and professional presence while leveraging the mother agency's inventory and resources. A Smart Solution for Expanding Travel Business Reach Built on Luxota's 10-in-1 OTA platform Enterprise Version, White-label Xpert is designed to enhance the marketing and sales capabilities of B2B travel agencies. By creating fully branded white-label platforms for their B2B clients, OTAs can now empower their partners to operate independently while benefiting from centralized service sourcing and advanced features. “With White-label Xpert, we aim to help agencies expand their reach and build stronger partnerships,” said Dr. Hadi, CEO of Luxota.“This solution enables B2B agencies to move beyond traditional sign-ins, offering their clients a complete operational platform that enhances both branding and profitability.” Key Features of White-label Xpert .Customizable Branding and Hosting: Agencies can offer platforms fully customized with their B2B clients' branding, logos, and contact information, hosted under their clients' domains. .Centralized Service Sourcing: Travel services in the white-labels are sourced directly from the mother agency, ensuring consistency and seamless integration. .Dynamic Pricing and Markup Control: White-label admins have full control over pricing strategies, allowing them to set markups and maximize profitability. .Multi-Currency and Multi-Language Capabilities: The platform supports global transactions, catering to diverse market demands. .Advanced Marketplace and Sales Tools: Robust tools streamline client management, accounting, and CRM, enabling efficient operations for both agencies and their B2B clients. Transforming B2B Relationships into Scalable Partnerships White-label Xpert is not just a tool; it's a transformative solution for travel agencies seeking to redefine their partnerships. By equipping B2B clients with fully operational platforms, OTAs enable them to independently manage sales and branding, creating scalable business models and fostering long-term growth. “White-label Xpert is a cost-effective, scalable solution for agencies looking to elevate their B2B offerings without investing in a full OTA platform,” Dr. Hadi added.“It's a testament to our commitment to empowering our partners with innovative, practical tools.” Why White-label Xpert Matters White-label Xpert simplifies operations, enhances global market reach, and drives profitability. It enables B2B clients to gain a professional edge in a competitive market, operating under their own domain while leveraging the mother agency's technology and inventory. Available Now on Luxota Market Exclusively available through Luxota Market, White-label Xpert is designed to meet the evolving needs of travel agencies worldwide. To learn more about how it can benefit your business, visit our main website at For further inquiries, you can reach our team via WhatsApp or phone at +971501386024 or email us at .... Company :-Luxota Travel Tech. User :- Luxota Press Email :... Phone :-+971501386024 Mobile:- 971501386024 MENAFN28122024003198003206ID1109037953 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Former Harford council member Guthrie accused of ‘secretive wrongful acts’ in new court documentsMost notable quotes of 2024

Jeffs' Brands: Fort (100%) Seeks to Revolutionizes E-Commerce with AI-Based Pest Control App and Bitcoin Payment IntegrationNoneZach Kittley finalizes agreement to take over as Florida Atlantic coach

SET-listed Thonburi Healthcare Group (THG) has denied involvement in the alleged multi-billion-baht fraud involving its founder and former chairman Boon Vanasin, his wife and a daughter, saying the case does not affect its business or operations. In a filing to the Stock Exchange of Thailand (SET) on Monday, THG's secretary Nattakan Jittinapat said Dr Boon resigned from his position as director and chairman of the company in August 2022 and currently holds no position or role in the firm's management. The statement followed news reports that the court issued arrest warrants against Dr Boon on charges of fraud and money laundering, as well as against his spouse Charuvarn Vanasin and their daughter Nalin. The hospital tycoon, who allegedly lured some 7.5 billion baht of investments in fake medical projects, has fled to China. Both Mrs Charuvarn and Ms Nalin, who currently serve as directors of the company, have voluntarily surrendered themselves to the police and denied the allegations by stating that the signatures on documents related to the allegations had been forged. "THG's operations remain unaffected and continue as normal without any impact on the company's business or activities," said Ms Nattakan. Currently, THG operates seven leading hospitals in Thailand and two overseas. According to the company's website, the group has 1,100 registered beds and a combined capacity to service 9,700 outpatients daily, making the group one of the leading healthcare providers in Thailand. "The company has not received any explanation from the two directors regarding the allegations reported in the media, nor have they expressed any intention to resign from their positions as directors of the company," she said. Based on the current facts and legal principles, the criminal charges against them do not disqualify them from serving as directors of the company, as the legal proceedings are ongoing and no final judgement has been rendered. "Nonetheless, the board recognises the importance of this matter and is closely monitoring developments to assess any potential impact on the company's reputation. The board may consider presenting this matter to the shareholders' meeting to deliberate on the qualifications and appropriateness of the two directors to continue serving in their roles." Shares of Thonburi surged as much as 21% in Bangkok on Monday, the biggest intraday advance since they began trading in 2017. Dr Boon, now 86, was fined by the Securities and Exchange Commission (SEC) when he was THG chairman in 2022 for misleading investors by disseminating false information. He was barred from serving as a director or executive in a public company for 42 months. While THG continues to operate with transparency and adhere to principles of good corporate governance, "the company advises all investors to exercise caution when receiving information not officially issued by the company and verify the source of such information before making any investment decisions," Ms Nattakan noted. NO INVOLVEMENT THG also denied the previous reports suggesting Dr Boon invested personal funds in the Jin Wellbeing County project in partnership with the company. "The investment in the Jin Wellbeing County project was solely undertaken by Thonburi Wellbeing Co Ltd, a subsidiary wholly owned by the company since the project's inception," said the statement. The investment in this project was approved by an extraordinary general meeting of shareholders in 2016, and the company has consistently reported its progress at annual shareholders' meetings and in its annual reports. Regarding reports of Dr Boon inviting investors to participate in five medical projects, THG clarified that all such investment solicitations were conducted solely by Dr Boon and the company is "not involved at all". The projects are a cancer centre in Pinklao, a wellness centre in Rama III, three hospitals in Laos, joint ventures with a hospital in Vietnam, and the establishment of a medical intelligence centre. THG initially got involved in signing a memorandum of understanding (MoU) for a joint venture project to establish a cancer centre, a post-surgery rehabilitation centre, a comprehensive elderly care centre, and a holistic health centre in the Pinklao area, along with a feasibility study for an investment in a hospital in Ho Chi Minh City, Vietnam. "These two projects were only at a preliminary study stage and the signing of an MoU. The company has thoroughly evaluated the feasibility plans for both projects and decided not to proceed with investments in either of them," the statement noted. Subsequent announcements about these projects were made by Dr Boon without the company's knowledge or involvement, it added. The SEC said on Monday that it has been closely monitoring Dr Boon's alleged fraud and initially found Dr Boon acted on his own and was not involved with THG. "Therefore, it may be considered a fraud under the Criminal Code, which does not yet fall under the Securities and Exchange Act BE 2535 [the Securities Act], which focuses on fraud in companies offering securities to the public," the regulator said in a statement. "If any actions that may fall under the Securities Act are found, the SEC will expedite the process and coordinate with the investigators." The SEC has investigated the actions that may be considered as an offence under the Securities Act. For example, THG disclosed information to the SET on Sept 20 regarding the discovery of suspicious transactions by a subsidiary of THG in making loans to companies related to the Vanasin family, including ordering products from a company registered in Singapore. But the actual goods were not delivered. CAUTION REQUIRED Stock market analysts advised investors to be extra cautious when investing in THG given the ongoing uncertainties. Daol Securities (Thailand) recommends avoiding investments in THG, while Tisco Securities recommends selling THG given a negative profit due to a large amount of provisions. The business restructuring has not yet materialised, resulting in weak revenue for many business units. It will still take a long time for revenue to recover because the business restructuring has not been fully implemented. "In addition, there are still cases related to the company's directors that still need time in order to consider the case," Tisco said. Dr Boon: Fined by the SEC in 2022

Donald Trump is returning to the world stage. So is his trolling

LanzaTech Appoints TechnipFMC’s Former Executive Chairman Thierry Pilenko to Board of Directors

UNITED KINGDOM - DECEMBER 23: Raindrops on glass (Photo by Tim Graham/Getty Images) It seems ridiculous to think that you could reduce something like amino acid interactions and resulting proteins to the level of something like Minecraft. In fact, I wouldn’t think most of us have even considered how generative AI could be applied to life science. But a few people behind the scenes are working diligently on figuring this out. Geoff von Maltzahn is at Flagship Pioneering, a company that’s working on the vanguard of high-tech life science. This venture capital firm has an incubator and teams of scientists and entrepreneurs working on things like mRNA and antibody therapeutics, as well as broader genomic projects. Flagship Pioneering works with companies like Seres Therapeutics and Indigo Agriculture, to innovate in places where breakthrough scientific progress can help with the biggest challenges that we as humans face. In a compelling TED talk, Maltzahn illustrates how all of this can work. He starts with a basic explanation of protein folding, where individual proteins emerge through a process of evolution that biologists tend to understand fairly well, while the rest of us have don’t have much of a clue. The World of Proteins Part of what I thought was so great about this talk was that Maltzahn really breaks down formidable scientific ideas into words that many people can easily understand. For example, in showing how a protein structure evolves, he notes that each protein starts out as a ‘noodle’ and then folds itself into useful forms. “This is the equivalent of, if your car, your refrigerator, your house, arrived as a noodle and folded itself into the form that you enjoy it in,” he says. Russian Officers Pulled Over For A Hasty Meeting. That’s When A Ukrainian HIMARS Opened Fire. Apple Cancels iPhone 14 And iPhone SE For Millions Of Users iOS 18.2.1 Release Date: New Apple iPhone Update Confirmed After explaining protein folding, he explains that new systems are able to generate models of proteins that fold in very precise ways. Maltzahn talks the prospect of about pursuing a ‘Shakespearean mastery’ of protein writing. His metaphor on precision and archery, again, boils down this type of innovation into a sort of visual reference in explaining how systems can center on the creation of precise antibodies: “It’s kind of like Robin Hood splitting the first arrow by firing an arrow right down the center of it, 50 times in a row,” he says. “And the reason that it has the potential to be valuable is: every time an antibody shows ... that it can provide a benefit to patients, humanity has a benefit, the ability to access the very best antibody.” In aid of talking about the best antibodies, he also goes over specifically how to react against the Covid virus that created the universal pandemic we all suffered through. He explains that to keep viruses from entering the cells, the technology can build antibodies that go after that portion that’s attaching to receptors. “This may be important to the next pandemic,” Maltzahn says. More New Science In addition, Maltzahn talks about creating new enzymes and analyzing things like the ‘tree of life of SARS viruses’ and how that will lead to very profound discoveries. “Maybe generative AI isn't just going to create beautiful cartoons and limericks to entertain ourselves and one another, and access knowledge that is already resident within humanity,” he posits. “It may just expand our access to new knowledge and new technologies in important ways.” How big will this be? The space of unexplored biology he explains is vast. Mentioning an analogy to the ‘great age of exploration’ with ships, he says we have worlds of knowledge to discover. “Even with generous assumptions around everything Mother Nature has ever had the chance to build and test throughout the entire history of evolution, all of her lab has tested less than the expanse of one drop of water relative to all of the Earth's oceans of possible protein sequences,” he says. “Think about that for just a second. Everybody in this room, every protein that makes our lives possible, every one of our ancestors and everything else in the living world that has ever been, fits into that one drop of water. ... if everything we know is in that one drop of water, if we find one more drop of water, that'll be a really big deal. But there really isn't a reason to believe that it's going to be limited to that, just imagine what could be.” I’ve seen and heard a lot about AI in the past year, but this is something fairly unique that really deserves a close look. We’re just beginning to understand how AI can create digital worlds that are vibrant, unique, and compelling, and how it can think like humans. But being able to create in a godlike way, using the building blocks of all life– well, to put it simply, that that’s something else.Smith asks to drop casesDonald Trump is returning to the world stage. So is his trollingreddit sport betting 。

AP Trending SummaryBrief at 4:43 p.m. ESTTHE WOODLANDS, TX, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix” or the "Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced the closing of its previously announced underwritten public offering of common stock units and pre-funded warrant units for aggregate gross proceeds of approximately $10.0 million, prior to deducting underwriting discounts and commissions and offering expenses, which amount includes the partial exercise of the over-allotment option granted to the underwriter. The equity offering was comprised of 615,500 common stock units (which included 156,809 common stock units issued upon exercise of the underwriter's over-allotment option) and 917,596 pre-funded warrant units, priced at a public offering price of $6.54 per common stock unit and $6.539 per pre-funded warrant unit. Each common stock unit and pre-funded warrant unit consisted of one share of common stock (or, in lieu of common stock, a pre-funded warrant to purchase one share of common stock at an exercise price of $0.001) and one warrant to purchase one share of common stock that expires on the five-year anniversary of the date of issuance (a "Series A Warrant"). The exercise price for the Series A Warrant is $6.54 per share. The warrants issued in this transaction were fixed priced and do not contain any variable pricing features. The securities comprising the units were immediately separable and were issued separately. Ladenburg Thalmann & Co. Inc. acted as the sole bookrunning manager for the offering. The Company intends to use the net proceeds from this offering to fund its clinical trial, for other research and development, for development of intellectual property, and for working capital. The securities described above were offered by the Company pursuant to a registration statement on Form S-1 (No. 333-282940), which was declared effective by the Securities and Exchange Commission (the "SEC”) on November 22, 2024. The offering was made solely by means of a prospectus. A final prospectus relating to and describing the terms of the offering was filed with the SEC on November 25, 2024 and is available on the SEC's website at http://www.sec.gov. Electronic copies of the final prospectus may be obtained from Ladenburg Thalmann & Co. Inc., 640 Fifth Avenue, 4th Floor, New York, New York 10019, or by telephone at (212) 409-2000, or by email at [email protected] . This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About Autonomix Medical, Inc. Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body. We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States. Forward Looking Statements Some of the statements in this release are "forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation the use of the anticipated proceeds from the offering. Such forward-looking statements can be identified by the use of words such as "should,” "might,” "may,” "intends,” "anticipates,” "believes,” "estimates,” "projects,” "forecasts,” "expects,” "plans,” and "proposes.” Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading "Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission ("SEC”) on May 31, 2024, and from time to time, our other filings with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law. Investor and Media Contact JTC Team, LLC Jenene Thomas 908-824-0775 [email protected]



Malik Nabers bemoans lack of early targets after ‘soft’ Giants’ blowout loss to Buccaneers

( MENAFN - ForPressRelease) Luxota, a leader in innovative travel technology, has officially launched White-label Xpert, enabling online travel agencies (OTAs) to offer fully branded, operational platforms to their B2B clients. This new solution is set to redefine how travel agencies collaborate with their partners by providing an independent and professional presence while leveraging the mother agency's inventory and resources. A Smart Solution for Expanding Travel Business Reach Built on Luxota's 10-in-1 OTA platform Enterprise Version, White-label Xpert is designed to enhance the marketing and sales capabilities of B2B travel agencies. By creating fully branded white-label platforms for their B2B clients, OTAs can now empower their partners to operate independently while benefiting from centralized service sourcing and advanced features. “With White-label Xpert, we aim to help agencies expand their reach and build stronger partnerships,” said Dr. Hadi, CEO of Luxota.“This solution enables B2B agencies to move beyond traditional sign-ins, offering their clients a complete operational platform that enhances both branding and profitability.” Key Features of White-label Xpert .Customizable Branding and Hosting: Agencies can offer platforms fully customized with their B2B clients' branding, logos, and contact information, hosted under their clients' domains. .Centralized Service Sourcing: Travel services in the white-labels are sourced directly from the mother agency, ensuring consistency and seamless integration. .Dynamic Pricing and Markup Control: White-label admins have full control over pricing strategies, allowing them to set markups and maximize profitability. .Multi-Currency and Multi-Language Capabilities: The platform supports global transactions, catering to diverse market demands. .Advanced Marketplace and Sales Tools: Robust tools streamline client management, accounting, and CRM, enabling efficient operations for both agencies and their B2B clients. Transforming B2B Relationships into Scalable Partnerships White-label Xpert is not just a tool; it's a transformative solution for travel agencies seeking to redefine their partnerships. By equipping B2B clients with fully operational platforms, OTAs enable them to independently manage sales and branding, creating scalable business models and fostering long-term growth. “White-label Xpert is a cost-effective, scalable solution for agencies looking to elevate their B2B offerings without investing in a full OTA platform,” Dr. Hadi added.“It's a testament to our commitment to empowering our partners with innovative, practical tools.” Why White-label Xpert Matters White-label Xpert simplifies operations, enhances global market reach, and drives profitability. It enables B2B clients to gain a professional edge in a competitive market, operating under their own domain while leveraging the mother agency's technology and inventory. Available Now on Luxota Market Exclusively available through Luxota Market, White-label Xpert is designed to meet the evolving needs of travel agencies worldwide. To learn more about how it can benefit your business, visit our main website at For further inquiries, you can reach our team via WhatsApp or phone at +971501386024 or email us at .... Company :-Luxota Travel Tech. User :- Luxota Press Email :... Phone :-+971501386024 Mobile:- 971501386024 MENAFN28122024003198003206ID1109037953 Legal Disclaimer: MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.

Former Harford council member Guthrie accused of ‘secretive wrongful acts’ in new court documentsMost notable quotes of 2024

Jeffs' Brands: Fort (100%) Seeks to Revolutionizes E-Commerce with AI-Based Pest Control App and Bitcoin Payment IntegrationNoneZach Kittley finalizes agreement to take over as Florida Atlantic coach

SET-listed Thonburi Healthcare Group (THG) has denied involvement in the alleged multi-billion-baht fraud involving its founder and former chairman Boon Vanasin, his wife and a daughter, saying the case does not affect its business or operations. In a filing to the Stock Exchange of Thailand (SET) on Monday, THG's secretary Nattakan Jittinapat said Dr Boon resigned from his position as director and chairman of the company in August 2022 and currently holds no position or role in the firm's management. The statement followed news reports that the court issued arrest warrants against Dr Boon on charges of fraud and money laundering, as well as against his spouse Charuvarn Vanasin and their daughter Nalin. The hospital tycoon, who allegedly lured some 7.5 billion baht of investments in fake medical projects, has fled to China. Both Mrs Charuvarn and Ms Nalin, who currently serve as directors of the company, have voluntarily surrendered themselves to the police and denied the allegations by stating that the signatures on documents related to the allegations had been forged. "THG's operations remain unaffected and continue as normal without any impact on the company's business or activities," said Ms Nattakan. Currently, THG operates seven leading hospitals in Thailand and two overseas. According to the company's website, the group has 1,100 registered beds and a combined capacity to service 9,700 outpatients daily, making the group one of the leading healthcare providers in Thailand. "The company has not received any explanation from the two directors regarding the allegations reported in the media, nor have they expressed any intention to resign from their positions as directors of the company," she said. Based on the current facts and legal principles, the criminal charges against them do not disqualify them from serving as directors of the company, as the legal proceedings are ongoing and no final judgement has been rendered. "Nonetheless, the board recognises the importance of this matter and is closely monitoring developments to assess any potential impact on the company's reputation. The board may consider presenting this matter to the shareholders' meeting to deliberate on the qualifications and appropriateness of the two directors to continue serving in their roles." Shares of Thonburi surged as much as 21% in Bangkok on Monday, the biggest intraday advance since they began trading in 2017. Dr Boon, now 86, was fined by the Securities and Exchange Commission (SEC) when he was THG chairman in 2022 for misleading investors by disseminating false information. He was barred from serving as a director or executive in a public company for 42 months. While THG continues to operate with transparency and adhere to principles of good corporate governance, "the company advises all investors to exercise caution when receiving information not officially issued by the company and verify the source of such information before making any investment decisions," Ms Nattakan noted. NO INVOLVEMENT THG also denied the previous reports suggesting Dr Boon invested personal funds in the Jin Wellbeing County project in partnership with the company. "The investment in the Jin Wellbeing County project was solely undertaken by Thonburi Wellbeing Co Ltd, a subsidiary wholly owned by the company since the project's inception," said the statement. The investment in this project was approved by an extraordinary general meeting of shareholders in 2016, and the company has consistently reported its progress at annual shareholders' meetings and in its annual reports. Regarding reports of Dr Boon inviting investors to participate in five medical projects, THG clarified that all such investment solicitations were conducted solely by Dr Boon and the company is "not involved at all". The projects are a cancer centre in Pinklao, a wellness centre in Rama III, three hospitals in Laos, joint ventures with a hospital in Vietnam, and the establishment of a medical intelligence centre. THG initially got involved in signing a memorandum of understanding (MoU) for a joint venture project to establish a cancer centre, a post-surgery rehabilitation centre, a comprehensive elderly care centre, and a holistic health centre in the Pinklao area, along with a feasibility study for an investment in a hospital in Ho Chi Minh City, Vietnam. "These two projects were only at a preliminary study stage and the signing of an MoU. The company has thoroughly evaluated the feasibility plans for both projects and decided not to proceed with investments in either of them," the statement noted. Subsequent announcements about these projects were made by Dr Boon without the company's knowledge or involvement, it added. The SEC said on Monday that it has been closely monitoring Dr Boon's alleged fraud and initially found Dr Boon acted on his own and was not involved with THG. "Therefore, it may be considered a fraud under the Criminal Code, which does not yet fall under the Securities and Exchange Act BE 2535 [the Securities Act], which focuses on fraud in companies offering securities to the public," the regulator said in a statement. "If any actions that may fall under the Securities Act are found, the SEC will expedite the process and coordinate with the investigators." The SEC has investigated the actions that may be considered as an offence under the Securities Act. For example, THG disclosed information to the SET on Sept 20 regarding the discovery of suspicious transactions by a subsidiary of THG in making loans to companies related to the Vanasin family, including ordering products from a company registered in Singapore. But the actual goods were not delivered. CAUTION REQUIRED Stock market analysts advised investors to be extra cautious when investing in THG given the ongoing uncertainties. Daol Securities (Thailand) recommends avoiding investments in THG, while Tisco Securities recommends selling THG given a negative profit due to a large amount of provisions. The business restructuring has not yet materialised, resulting in weak revenue for many business units. It will still take a long time for revenue to recover because the business restructuring has not been fully implemented. "In addition, there are still cases related to the company's directors that still need time in order to consider the case," Tisco said. Dr Boon: Fined by the SEC in 2022

Donald Trump is returning to the world stage. So is his trolling

LanzaTech Appoints TechnipFMC’s Former Executive Chairman Thierry Pilenko to Board of Directors

new sport betting sites

sport betting reddit

Related articles:
Latest News
Recommended Reading
Hot Recommendations
jollibee 6 pcs www jilibet.com

Copyright © 2015 jilibet slots All Rights Reserved.